3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neuroblastoma
28
Glioblastoma
16
Gliosarcoma
12
Central Nervous System Neoplasms
10
Brain Neoplasms
10
Astrocytoma
10
Glioma
7
Oligodendroglioma
6
Medulloblastoma
5
Ganglioneuroblastoma
5
Lymphoma
4
Familial ependymoma
4
Ependymoma
4
Sarcoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neuroectodermal Tumors, Primitive
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Burkitt Lymphoma
3
Wilms Tumor
2
Testicular Neoplasms
2
Testicular Germ Cell Tumor
2
Sezary Syndrome
2
Rhabdoid Tumor
2
Ovarian Neoplasms
2
Interventions
sargramostim
1
Temozolomide
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Tetanus
×
sargramostim
×
CNS
×
Clear all
NCT03927222
2024-04-08
I-ATTAC
Duke University
Phase 2
Terminated
6 enrolled
7 charts